AGC Biologics partners with Takara Bio to manufacture Plasmid DNA vaccine against COVID-19

AGC Biologics | May 22, 2020

  • AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals, has announced its partnership with Takara Bio.

  • The companies will partner in the fight against COVID-19 by collaborating on a prophylaxis DNA vaccine, with AGC Biologics manufacturing the plasmid DNA intermediate for the vaccine.

  • The vaccine will be developed based on Osaka University and AnGes, Inc.'s expertise of developing plasmid DNA products.


AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals, has announced its partnership with Takara Bio.The companies will partner in the fight against COVID-19 by collaborating on a prophylaxis DNA vaccine, with AGC Biologics manufacturing the plasmid DNA intermediate for the vaccine.

We are working hard in this fight against COVID-19. We are grateful for the support of AGC Biologics. This partnership will help us move safely and quickly in the development of this vaccine.

- Takara Bio's CEO Koichi Nakao


The vaccine will be developed based on Osaka University and AnGes, Inc.'s expertise of developing plasmid DNA products.

AGC Biologics is delighted to be working with Takara Bio on a project that will make a big difference for countless people. Our organization looks forward to partnering with Takara Bio to successfully fight this global threat.

- AGC Biologics CBO Mark Womack


With manufacturing facilities in Asia, Europe and the United States, AGC Biologics brings decades of experience as a CDMO, including providing commercial market supply with PDMA, EMA and FDA approvals. To serve the rapidly growing demand for pDNA, AGC Biologics offers a 10-year proven track record in commercial plasmid production and a highly customizable approach for all plasmid needs.

About Takara Bio

Takara Bio Inc. began as the biomedical business unit of Takara Shuzo Co., Ltd. (now Takara Holding Inc.). Based on the Company's mission – Contributing to the health of humankind through the development of revolutionary biotechnologies such as gene therapy – Takara Bio focuses on two business segments that utilize its core biotechnology and encourage broader expansion: the Bioindustry Business, the basis for stable earning providing research reagents, scientific instruments, and various contracted services to life science researchers at universities and companies worldwide; and the Gene Therapy Business, the segment that the Company views as the foundation for future growth developing and commercializing gene therapies for cancer, and so on. Takara Bio has two large-scale GMP/GCTP compatible facilities CGCP I & II (Center for Gene and Cell Processing), that develops and manufactures products such as regenerative medicine and biopharmaceuticals, and cooperates in the production of this preventive DNA vaccine.

About AGC Biologics

AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), with a strong commitment to deliver the highest standard of service to our clients and partners. The company currently employs more than 1000 employees worldwide. AGC Biologics extensive network spans three continents, with cGMP-compliant facilities in Seattle, Washington; Copenhagen, Denmark; Heidelberg, Germany; and Chiba, Japan.

AGC Biologics offers deep industry expertise and unique customized services for the scale-up and cGMP manufacture of protein-based therapeutics; from pre-clinical to commercial mammalian and microbial production. Our integrated service offerings include cell line development, bioprocess development, formulation, analytical testing, antibody drug development and conjugation, cell banking and storage, and protein expression - including our proprietary CHEF1® Expression System for mammalian production.

Spotlight

Molecular Biotechnology is a growing field within Life science that combines applications from e.g. molecular biology, cell biology, microbiology, biochemistry and immunology, in order to generate products and services within the area of medicine, agriculture and food.

Spotlight

Molecular Biotechnology is a growing field within Life science that combines applications from e.g. molecular biology, cell biology, microbiology, biochemistry and immunology, in order to generate products and services within the area of medicine, agriculture and food.

Related News

MEDICAL

United Health Foundation Partners With Harris-Stowe State University to Create New Bioinformatics Program

Harris-Stowe State University, United Health Foundation | November 20, 2021

The United Health Foundation, the philanthropic foundation of UnitedHealth Group (NYSE: UNH), has awarded a $2 million, three-year grant to Harris-Stowe State University to create a bioinformatics program for undergraduate students at the historically Black university located in St. Louis. Bioinformatics is an emerging field that combines science, physics, math and biology to aid in the diagnosis, treatment and discovery of new therapeutic advancements. An example of bioinformatics is the use of computer analysis on the Human Genome Project, which has recorded the 3 billion basic pairs of the human DNA system. HSSU will develop a new undergraduate program to train students for careers as bioinformatics professionals. HSSU will use the support to Develop new curricula combining coursework and experiential learning opportunities. Expose high school students in surrounding school districts to the field of bioinformatics through a summer bioinformatics “boot camp” program. Offer academic scholarships for up to 25 students each year. “In the past decade, Harris-Stowe State University has emerged as a leader in training students for high-tech careers. This new program will help us to build on that important work, as well as continue to fulfill our mission of serving historically underrepresented students. Bioinformatics is a rapidly growing field of study, and it is vital for all people to play a role in its advancement.” Dr. LaTonia Collins Smith, interim president of HSSU Studies have shown that there is a substantial gap in the number of diverse college students trained in biomedical sciences. Black, Hispanic and Native American people account for only 7.1% of the employed biological/biomedical and life sciences workforce, according to the National Science Foundation. A diverse health workforce helps provide personalized, culturally competent care to an increasingly diverse population. “The United Health Foundation is honored to collaborate with Harris-Stowe State University to increase the diversity of the life sciences workforce. We are excited about HSSU training students who will make discoveries, develop therapies and advance health care for all,” said Patrick Quinn, CEO of UnitedHealthcare in Missouri, a UnitedHealth Group company. “This partnership illustrates UnitedHealth Group’s commitment to health equity and to building a diverse health workforce reflective of our society.” The commitment in Missouri is one of many ways UnitedHealth Group is working to advance health equity by diversifying the health workforce of the future. The United Health Foundation’s Diverse Scholars Initiative, for example, partners with nine nonprofit and civic organizations and has provided over 3,000 scholarships to diverse students studying medicine and public health across the U.S. since 2007. Optum Technology, part of Optum which is a UnitedHealth Group company, offers a mentor-led STEM program that has provided science, technology, engineering and mathematics training to over 7,000 diverse and underrepresented students at 103 middle and high schools since 2019. To learn more about the company’s commitment to health equity as well as its efforts to build healthier communities, improve outcomes and create a modern, high-performing health care system. About Harris-Stowe State University For over 160 years, Harris-Stowe State University (HSSU) has served the historically underrepresented. As a Historically Black College and University, HSSU is strongly committed to providing a high-quality higher education experience that is both affordable and accessible to the diverse populations within and beyond the metropolitan St. Louis region. More than 90% of student population are racially and ethnically diverse and receive some form of financial aid. About the United Health Foundation Through collaboration with community partners, grants and outreach efforts, the United Health Foundation works to improve our health system, build a diverse and dynamic health workforce and enhance the well-being of local communities. The United Health Foundation was established by UnitedHealth Group (NYSE: UNH) in 1999 as a not-for-profit, private foundation dedicated to improving health and health care. To date, the United Health Foundation has committed more than $500 million to programs and communities around the world.

Read More

Bioclean Innovations and rep-l® Antimicrobials Partners to Launch a Powerful Non-toxic Bio-based Antimicrobial Product Line

Bioclean Innovations | October 19, 2020

Bioclean Innovations Inc, a Biotech startup focused on innovative antimicrobial solutions to combat disease outbreaks has partnered with rep-L® Antimicrobials, to launch a powerful but non-toxic bio-based antimicrobial product line. Our rep-L-based disinfectants are designed to create a new methodology for addressing the infection control challenges facing the education and long-term health care sectors today. The SARS-CoV-2 virus responsible for the COVID-19 pandemic is one of an increasing number of pathogens and antibiotic-resistant infections society is facing. Schools, universities, and care homes rely on a frequent cleaning and disinfection process which now requires more cleaning and disinfectant products and more labor while still leaving the risks of microbial transmission from contamination occurring on the surface in between disinfection cycles. Bioclean has developed a range of products, including continuously-active disinfectant, hand sanitizer, and disinfectant wipes that can kill and protect against viruses, bacteria, and fungi for thirty (30) days and longer, eliminating the need for frequent disinfection and providing effective, long-lasting protection on high touch surfaces and hands.

Read More

CELL AND GENE THERAPY

Sartorius Stedim Biotech Strengthens its Product Portfolio for Cell and Gene Therapies by Acquiring a Majority Stake in CellGenix

Sartorius | July 05, 2021

Sartorius Stedim Biotech, a leading international biopharmaceutical partner, has acquired a majority stake in CellGenix GmbH, a reagent manufacturer. The company, headquartered in Freiburg, Germany, and with a sales subsidiary near the biotechnology center in Boston, Massachusetts, USA, manufactures and distributes cell culture components in GMP grade for the manufacture of cell and gene therapy products. Sartorius Stedim Biotech originally purchased 51% of this company, which was previously privately held, for about 100 million euros in cash. Sartorius Stedim Biotech plans to purchase the remaining CellGenix shares in 2023 and 2026. CellGenix, founded in 1994 at the University Medical Center of Freiburg, employs about 70 employees and aims to produce revenues of more than 20 million euros in 2020, with a very high double-digit EBITDA margin. Sartorius Stedim Biotech intends to significantly expand the Freiburg facility and establish it as a center of excellence within the company to develop and produce high-quality critical raw materials for the cell and gene therapy markets. This press release includes forward-looking statements regarding the Sartorius Stedim Biotech Group's future development. Forward-looking statements include known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or indicated by such statements. Sartorius Stedim Biotech disclaims all obligation for revising such statements in light of new information or future events. The following is a translation of the original French news release. Sartorius Stedim Biotech accepts no responsibility for the accuracy of this translation. The legally binding version is the original French news release. Sartorius Stedim Biotech's profile Sartorius Stedim Biotech is a leading international biopharmaceutical industry partner. As a complete solutions provider, the business helps its clients produce biotech medications in a safe, timely, and cost-effective manner. Sartorius Stedim Biotech, headquartered in Aubagne, France, is listed on the Eurolist of Euronext Paris. Sartorius Stedim Biotech has a worldwide reach thanks to its production and R&D facilities in Europe, North America, Asia, and an international network of sales companies. The Group's yearly growth rate has been in the double digits on average, and it has constantly been extending its portfolio via acquisitions of related technology. In 2020, the business had about 7,500 employees and a sales revenue of 1,910 million euros.

Read More